Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Fineline Cube Jan 15, 2026
Company Deals

Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis

Fineline Cube Jan 15, 2026
Company Deals

Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases

Fineline Cube Jan 15, 2026
Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Fineline Cube Jan 15, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Company Drug

Zai Lab Presents ZL-1310 Clinical Results for Small Cell Lung Cancer at ASCO

Fineline Cube Jun 3, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) presented the latest results from the...

Company Drug

Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting

Fineline Cube Jun 3, 2025

Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...

Company Drug

Innovent Biologics Presents IBI363 Clinical Results at 2025 ASCO Annual Meeting

Fineline Cube Jun 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the oral presentation of results from two clinical...

Company Drug

BeOne Medicines Wins Conditional Approval for Ziihera in HER2-Positive BTC

Fineline Cube Jun 3, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...

Company Deals

LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies

Fineline Cube Jun 3, 2025

China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million...

Company Deals

Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy

Fineline Cube Jun 3, 2025

Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced...

Company Deals

Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights

Fineline Cube Jun 3, 2025

US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical...

Company Drug

MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting

Fineline Cube Jun 3, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) last week presented results from the dose...

Company Deals

Hanx Bio Files for Hong Kong IPO with ICBC International as Sole Sponsor

Fineline Cube Jun 3, 2025

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. this week made another initial public offering (IPO) filing...

Company Drug

R&B Biotech Receives FDA Approval for ZS805 Gene Therapy in Fabry Disease

Fineline Cube Jun 3, 2025

Sichuan R&B Biotech, a China-based biotech firm, announced receiving clinical approval from the US Food...

Company Drug

GSK’s Linerixibat NDA Accepted by FDA for Cholestatic Pruritus in PBC Patients

Fineline Cube Jun 3, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that the New Drug Application (NDA) for...

Company Deals

Shanghai Ark Bio and Partex Collaborate on ATR Inhibitor AK0658 Development

Fineline Cube Jun 3, 2025

China’s Shanghai Ark Biopharmaceutical Co., Ltd. has entered into a new cooperation agreement with Germany-based...

Company Drug

Bayer Files for Approval of Gadoquatrane MRI Contrast Agent in Japan

Fineline Cube Jun 3, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) this week filed a marketing application with Japan’s...

Company Deals

MicroPort CardioFlow to Acquire 49% Stake in La Ronda for RMB 171 Million

Fineline Cube Jun 3, 2025

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company

MSD Appoints Kyle Tattle as President of China Operations

Fineline Cube May 30, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced leadership changes in its China and...

Company Drug

Zelgen’s Jaktinib Receives NMPA Approval for Myelofibrosis Treatment

Fineline Cube May 30, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received marketing approval from...

Others

MSD and Daiichi Sankyo Withdraw US Filing for Patritumab Deruxtecan in EGFR-Mutated NSCLC

Fineline Cube May 30, 2025

Partners Merck, Sharp & Dohme (MSD; NYSE: MRK) and Daiichi Sankyo (TYO: 4568) announced the...

Company Drug

Fosun Pharma’s FCN-159 and FCN-437c Win NMPA Marketing Approvals

Fineline Cube May 30, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the receipt of marketing...

Company Deals

CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals

Fineline Cube May 30, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with...

Company Medical Device

Acotec Scientific’s E-Peridge Balloon Catheter Approved by China’s NMPA

Fineline Cube May 30, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...

Posts pagination

1 … 95 96 97 … 610

Recent updates

  • WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development
  • ABM Therapeutics Licenses MEK1/2 Inhibitor ABM‑168 to Mosaica Medicines for Global Development
  • WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership
  • Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis
  • Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Company Digital

ABM Therapeutics Licenses MEK1/2 Inhibitor ABM‑168 to Mosaica Medicines for Global Development

Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Company Deals

Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.